A Phase 4 clinical trial evaluating terlipressin was updated to completed status on October 13, 2026. The study, titled "Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients," is registered under identifier NCT06108362.
The trial examined terlipressin's relationship to early postoperative acute kidney injury in patients undergoing liver transplantation. It was conducted as a Phase 4 study, meaning it took place after the drug's approval and marketing for its indicated use.
The registry listing reflects a status change to completed as of the date given. No results, outcomes, or efficacy data are included in this status update. The completion designation indicates the study has concluded its planned activities, but it does not by itself confirm what, if any, findings were observed regarding kidney injury incidence.
Readers interested in the background of terlipressin, including its approved regulatory status, can consult the compound overview for further context.